ACR / en Moving the Conversation Forward in Rheumatology – ֳ at ACR Convergence 2022 /about-ucb/magazine/detail/article/moving-the-conversation-forward-in-rheumatology-ucb-at-acr-convergence-2022 <span>Moving the Conversation Forward in Rheumatology – ֳ at ACR Convergence 2022</span> <div class="field field--name-field-newsroom-author-title field--type-string field--label-above field__items"> John Ioannou, Medical Affairs, Rheumatology </div> <span><span lang about="/user/8671" typeof="schema:Person" property="schema:name" datatype content="Nathalie.Vandenbruaene@ucb.com">Vandenbruaene …</span></span> <span><time datetime="2022-11-10T11:59:00+01:00" title="Thursday 10 November 2022 - 11:59">Thu 10/11/2022 - 11:59</time> </span> <div class="field field--name-field-newsroom-author-image field--type-entity-reference field--label-above field__items"> <article class="media media--type-image media--view-mode-default"> <div class="field field--name-image field--type-image field--label-hidden field__items"> <img loading="lazy" src="/sites/default/files/styles/ucb_header_image/public/2022-06/John.jpg.webp?itok=WDlmnK6F" width="100" height="95" typeof="foaf:Image"> </div> </article> </div> <div class="field field--name-field-newsroom-content field--type-text-long field--label-above field__items"> <article data-quickedit-entity-id="media/44296" class="align-center media media--type-image media--view-mode-default"> <div class="field field--name-image field--type-image field--label-hidden field__items"> <img loading="lazy" src="/sites/default/files/styles/ucb_header_image/public/2022-11/Jeffrey_John_.PNG.webp?itok=ji52AkNp" width="1021" height="351" typeof="foaf:Image"> </div> </article> <p>The American College of Rheumatology (ACR) annual meeting – ACR Convergence 2022 – &nbsp; takes place this week (November 10-14) in Philadelphia, Pennsylvania. We sat down with Dr. Jeff Stark, Head of Medical Immunology, U.S., ֳ and Dr. John Ioannou, Head of Global Medical Affairs, Rheumatology, ֳ to hear more about the meeting and ֳ’s presence.<br> &nbsp;</p> <p><strong>What can you tell us about ACR Convergence 2022?</strong></p> <p><strong>Jeff Stark, MD</strong>: “ACR Convergence 2022 is one of the most highly anticipated meetings in the 2022 rheumatology calendar, offering an innovative experience to attendees. For the first time in three years, delegates can attend this year’s meeting either in-person, with all the opportunities for discussions through direct interaction, or they can view content virtually and on demand. The scientific program, with presentations led by worldwide rheumatology experts, includes the highest impact research that will challenge current thinking and medical practice. We are looking forward to meeting our friends and colleagues in-person to present new research, discuss new findings, and experience the latest updates in rheumatology.”</p> <p><strong>Can you share more about ֳ’s presence at ACR Convergence 2022?</strong></p> <p><strong>John Ioannou, MD, Ph.D.</strong>: “ֳ is excited and proud to have a strong scientific presence at ACR Convergence 2022, with 15 accepted abstracts across our portfolio, including late-breaking data in psoriatic arthritis and axial spondyloarthritis. Our abstracts have been accepted as four oral presentations, eight e-posters, and three ‘Ignite Talks’ which are five-minute, in-person poster presentations dedicated to the highest ranked posters at the meeting. We are also hosting a medical symposium – Rheum for Improvement: axial SpA and PsA – where a distinguished faculty of leading rheumatologists will discuss treatment landscapes, treatment targets and strategies that can improve patient care in axial spondyloarthritis and psoriatic arthritis.”&nbsp;</p> <p><strong>What can healthcare professionals expect to experience at the ֳ medical booth?</strong></p> <p><strong>Jeff Stark, MD</strong>: “We look forward to welcoming healthcare professionals to the ֳ medical booth, where our colleagues will be pleased to interact and answer questions. We are also excited to introduce healthcare professionals to a tour of the RheuMuseum, the theme of our medical booth, where they can explore a series of engaging exhibits on psoriatic arthritis and axial spondyloarthritis that delve into the clinical manifestations, immunobiology and cytokine pathways.”</p> <p><strong>What do you see as the future of rheumatology?</strong></p> <p><strong>Jeff Stark, MD</strong>: “Tremendous advances have been made in rheumatology and the management of chronic, inflammatory conditions such as psoriatic arthritis and axial spondyloarthritis. However, we still need to understand how these diseases can be identified, diagnosed and treated earlier. Ultimately, our goal is to create a brighter future for people living with rheumatic diseases, which will be shaped by a deeper understanding of patients’ needs and applying new clinical knowledge to meet the specific needs of each individual.”&nbsp;</p> <p><strong>John Ioannou, MD, Ph.D.</strong>: “These are exciting times for rheumatology. A deeper understanding of the pathophysiology behind conditions such as psoriatic arthritis and axial spondyloarthritis has allowed scientists to develop innovative approaches to disease management. At ֳ we continue our commitment to a future of ongoing research to find innovative solutions, with the goal of elevating the standard of care and optimizing outcomes for people living with chronic rheumatic diseases.”</p> <p><strong>Jeff, if you had one final message for the audience what would it be?</strong></p> <p><strong>Jeff Stark, MD: </strong>“ACR Convergence 2022 promises to be a stimulating meeting with multiple learning experiences to expand our collective knowledge. At this meeting and beyond, we look forward to continuing our collaboration with the rheumatology community so that together we can deliver innovative new solutions that put patient needs at the center. We look forward to meeting you in person in Philadelphia.” &nbsp;</p> <p><br> You can stay up to date on the latest ֳ news at ACR Convergence 2022 through our social media channels (<a href="https://twitter.com/ucb_news">Twitter</a>, <a href="https://www.linkedin.com/company/ucb-pharma">LinkedIn</a>).<br> &nbsp;</p> </div> <div class="field field--name-field-newsroom-category field--type-entity-reference field--label-above field__items"> <a href="/taxonomy/term/1907" hreflang="en">about ucb</a> </div> <div class="field field--name-field-newsroom-tags field--type-entity-reference field--label-above field__items"> <a href="/taxonomy/term/1484" hreflang="en"> ACR</a> <a href="/taxonomy/term/10314" hreflang="en">American College of Rheumatology</a> <a href="/taxonomy/term/1395" hreflang="en"> rheumatology</a> </div> <div> <div class="comments-wrapper"> <div class="comment-area"> <h2 class="red">Leave a Comment</h2> <drupal-render-placeholder callback="comment.lazy_builders:renderForm" arguments="0=node&amp;1=14713&amp;2=field_newsroom_askexpert&amp;3=ask_expert" token="ecrIMojj00Ycp8rd3keCiClNJvoS9RVICW6tGdYvh9A"></drupal-render-placeholder> <span class="toggle-form js-toggle-form"></span> </div> </div> </div> <span class="a2a_kit a2a_kit_size_16 addtoany_list" data-a2a-url="/about-ucb/magazine/detail/article/moving-the-conversation-forward-in-rheumatology-ucb-at-acr-convergence-2022" data-a2a-title="Moving the Conversation Forward in Rheumatology – ֳ at ACR Convergence 2022"><a class="a2a_dd addtoany_share" href="https://www.addtoany.com/share#url=https%3A%2F%2Fwww.ucb.com%2Fabout-ucb%2Fmagazine%2Fdetail%2Farticle%2Fmoving-the-conversation-forward-in-rheumatology-ucb-at-acr-convergence-2022&amp;title=Moving%20the%20Conversation%20Forward%20in%20Rheumatology%20%E2%80%93%20ֳ%20at%20ACR%20Convergence%202022"></a><a class="a2a_button a2a_button_facebook"><img src="/themes/custom/ucb_premier/images/a2a/facebook-icon.svg" width="16" height="16" border="0" alt="linkedin"></a><a class="a2a_button a2a_button_linkedin"><img src="/themes/custom/ucb_premier/images/a2a/linkedin-icon.svg" width="16" height="16" border="0" alt="linkedin"></a><a class="a2a_button a2a_button_twitter"><img src="/themes/custom/ucb_premier/images/a2a/twitter-icon.svg" width="16" height="16" border="0" alt="twitter"></a></span> <div class="field field--name-field-like field--type-likes-dislikes field--label-above field__items"> <div class="like_dislike"> <div class="like"> <a rel="nofollow" class="use-ajax" href="/like-dislike/like/eyJlbnRpdHlfdHlwZSI6Im5vZGUiLCJlbnRpdHlfaWQiOiIxNDcxMyIsImZpZWxkX25hbWUiOiJmaWVsZF9saWtlIiwibGlrZXMiOiIzODAiLCJkaXNsaWtlcyI6Ii0zOSJ9"></a> <span class="like-14713"> 380 Likes </span> </div> </div> <div id="like_dislike_status"></div> </div> Thu, 10 Nov 2022 10:59:00 +0000 Vandenbruaene Nathalie 14713 at